Ro 48-8071

[1]Morand OH, et al. Ro 48-8.071, a new 2,3-oxidosqualene:lanosterol cyclase inhibitor lowering plasma cholesterol in hamsters, squirrel monkeys, and minipigs: comparison to simvastatin. J Lipid Res. 1997 Feb;38(2):373-90.|[2]Liang Y, et al. Cholesterol biosynthesis inhibitor RO 48-8071 suppresses growth of hormone-dependent and castration-resistant prostate cancer cells. Onco Targets Ther. 2016 May 30;9:3223-32|[3]Liang Y, et al. Cholesterol biosynthesis inhibitors as potent novel anti-cancer agents: suppression of hormone-dependent breast cancer by the oxidosqualene cyclase inhibitor RO 48-8071. Breast Cancer Res Treat. 2014 Jul;146(1):51-62.|[4]Chuang JC, et al. Sustained and selective suppression of intestinal cholesterol synthesis by Ro 48-8071, an inhibitor of 2,3-oxidosqualene:lanosterol cyclase, in the BALB/c mouse. Biochem Pharmacol. 2014 Apr 1;88(3):351-63.ACS Synth Biol. 2023 Feb 28.|Cancer Cell. 2023 May 23;S1535-6108(23)00142-3.|Mol Cell. 2021 Jul 1;81(13):2736-2751.e8.|Nat Commun. 2023 Jul 17;14(1):4267.|Oncotarget. 2017 Feb 28;8(9):14860-14875.|Sci China Life Sci. 2021 May 27;1-21.|Cancer Res Commun. 2024 Jul 19.|Cell Death Dis. 2021 May 13;12(5):482.|Cell Rep. 2022 Dec 13;41(11):111827.|ImmunoMedicine. 2022 Dec.|Mol Med Rep. 2021 Dec;24(6):828.